SCHEMBL480388

SCHEMBL480388

CCCc1c(O)ccc(C(C)=O)c1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50
PRKCI P41743 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
PPARG P37231 2/20 0.49
PPARD Q03181 2/20 0.49
PPARA Q07869 2/20 0.49
LMNA P02545 2/20 0.49
MAPT P10636 1/20 0.49
NFKB1 P19838 1/20 0.49
BLM P54132 1/20 0.49
GRM2 Q14416 1/20 0.49
CYSLTR2 Q9NS75 13/20 0.48
CYSLTR1 Q9Y271 13/20 0.48
MEN1 O00255 1/20 0.45
GLA P06280 1/20 0.45
CYP3A4 P08684 1/20 0.45
ALOX5 P09917 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30736074 1.00 CYP1A2 (0.50) CYP1A2CYP2C9PRKCIALDH1A1CYP2D6
SCHEMBL7041417 0.95 CYP1A2 (0.47) CYP1A2CYP2C9PRKCIALDH1A1CYP2D6
SCHEMBL10975179 0.89 CYP1A2 (0.48) CYP1A2CYP2C9PRKCIALDH1A1CYP2D6
SCHEMBL9121697 0.88 CYP1A2 (0.47) CYP1A2CYP2C9PRKCIALDH1A1CYP2D6
SCHEMBL9814053 0.86 TYR (0.49) CYP1A2CYP2C9ALDH1A1CYP2D6CYP2C19
SCHEMBL9814064 0.86 TYR (0.49) CYP1A2CYP2C9ALDH1A1CYP2D6CYP2C19
SCHEMBL9814051 0.86 TYR (0.49) CYP1A2CYP2C9ALDH1A1CYP2D6CYP2C19
SCHEMBL10726758 0.85 SELL (0.53) CYP1A2CYP2C9PRKCIALDH1A1PPARG
SCHEMBL2009246 0.85 ALDH1A1 (0.53) CYP1A2CYP2C9PRKCIALDH1A1CYP2D6
SCHEMBL13452821 0.84 PPARG (0.48) CYP1A2CYP2C9PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12269909-B2 Polymer composition and a method of preparing a polymer resin AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2025-04-08 US claimed
US-20220041781-A1 A Polymer Composition and a Method of Preparing a Polymer Resin AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2022-02-10 US claimed
WO-2020130941-A1 A POLYMER COMPOSITION AND A METHOD OF PREPARING A POLYMER RESIN AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2020-06-25 WO claimed
EP-1817301-B1 POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2012-02-01 EP claimed
US-7598423-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-10-06 US claimed
US-20080139505-A1 Potentiators Of Glutamate Receptors ARRAY BIOPHARMA, INC. 2008-06-12 US claimed
EP-1817301-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-15 EP claimed
WO-2006057870-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2006-06-01 WO claimed
EP-1086079-B1 DERIVATIVES OF HYDROXYPHENYLSULFANYLBENZOIC AND HYDROXYPHENYLSULFANYLARYLACETIC ACIDS LECIVA A S (CZ) 2003-05-07 EP claimed
US-6461417-B1 Ink compositions XEROX CORPORATION 2002-10-08 US claimed
US-6303612-B1 USED AS ANTIINFLAMMATORY AND/OR ANTIASTHMATIC AGENTS LECIVA, A.S. (CZ) 2001-10-16 US claimed
EP-1086079-A1 DERIVATIVES OF HYDROXYPHENYLSULFANYLBENZOIC AND HYDROXYPHENYLSULFANYLARYLACETIC ACIDS Leciva, A.S. (CZ) 2001-03-28 EP claimed
WO-1999067208-A1 DERIVATIVES OF HYDROXYPHENYLSULFANYLBENZOIC AND HYDROXYPHENYLSULFANYLARYLACETIC ACIDS LECIVA, A.S. (CZ) 1999-12-29 WO claimed
EP-0242230-B1 Pyrido [1,2-a] pyrimidine derivatives TOKYO TANABE COMPANY LIMITED (JP) 1990-10-03 EP claimed
EP-0217673-B1 Pyrido [1,2-a]pyrimidine derivatives TOKYO TANABE COMPANY LIMITED (JP) 1989-12-27 EP claimed
EP-0242230-A2 Pyrido [1,2-a] pyrimidine derivatives TOKYO TANABE COMPANY LIMITED (JP) 1987-10-21 EP claimed
EP-0217673-A1 Pyrido [1,2-a]pyrimidine derivatives TOKYO TANABE COMPANY LIMITED (JP) 1987-04-08 EP claimed
JP-1193223-A None JP disclosed
US-4136192-A ANTIALLERGENS BEECHAM GROUP LIMITED (GB) 1979-01-23 US disclosed
US-4133889-A ANAPHYLAXIS ANTAGONISTS FISONS, LTD. (GB) 1979-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139505-A1 Potentiators Of Glutamate Receptors GRM1, GRIN1, GRM2 CYP1A2 1022/4885CYP2C9 890/4885PRKCI 2743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.